ArticleHuman mutation2026
Clinically Translatable Mutation-Based Biomarkers in Ascending Aortic Aneurysm: A Bibliometric Study.
Article in Human mutation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinically Translatable Mutation-Based Biomarkers in Ascending Aortic Aneurysm: A Bibliometric Study.Human mutation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ascending aortic aneurysm is often clinically silent until rupture or acute dissection, and reliance on diameter-based thresholds leaves substantial risk heterogeneity that may be reduced by genetic variant-informed biomarkers. In plain language, clinically translatable variant biomarkers are genetic findings that can change diagnosis, family screening, surveillance intensity, or prophylactic surgical timing. We performed a cross-database bibliometric study to delineate the intellectual structure and thematic evolution of clinically translatable variant-based biomarker research in ascending aortic aneurysm. Web of Science Core Collection, Scopus, and PubMed were queried using concept-driven terms spanning thoracic/ascending aneurysm phenotypes, genomic variation, and biomarker/clinical translation; searches and exports were executed on January 10, 2026, for publications from 1997 to 2025. After harmonization, deduplication, and adjudicated screening of titles/abstracts and metadata, 1346 eligible journal articles and reviews were analyzed using bibliometrix and VOSviewer to compute productivity/impact indicators and construct co-authorship, co-citation, and keyword co-occurrence networks with temporal overlays. The literature exhibited rapid growth (15.35% annual growth rate) across 478 sources, with a mean of 8.94 co-authors per document, 24.67% international co-authorship, an average article age of 9.28 years, and 30.68 citations per article. The United States was the dominant hub (405 articles and 17,383 citations), with a densely connected Western European cluster and accelerating output from China (155 articles) but lower citation intensity. Conceptual cores were anchored in syndromic and heritable thoracic aortic disease genetics (e.g., Marfan and Loeys-Dietz syndromes; FBN1 and TGF-beta signaling), increasingly linked to diagnosis, variant interpretation, risk stratification, guidelines, and management. Life cycle modeling suggested an approach to publication peak around 2028, implying a shift from gene discovery toward variant interpretation, implementation, and equity-conscious validation. Notably, peripheral participation from low-resource regions remained sparse overall.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.